3/24
10:03 am
nktr
Rating for NKTR
Low
Report
Rating for NKTR
3/24
10:03 am
nktr
Rating for NKTR
Low
Report
Rating for NKTR
3/24
09:00 am
nktr
Nektar Therapeutics (NKTR) is now covered by Wedbush. They set a "neutral" rating and a $70.00 price target on the stock.
Low
Report
Nektar Therapeutics (NKTR) is now covered by Wedbush. They set a "neutral" rating and a $70.00 price target on the stock.
3/24
09:00 am
nktr
Nektar Therapeutics (NKTR) is now covered by Wedbush. They set a "neutral" rating and a $70.00 price target on the stock.
Low
Report
Nektar Therapeutics (NKTR) is now covered by Wedbush. They set a "neutral" rating and a $70.00 price target on the stock.
3/24
07:14 am
nktr
Nektar initiated with a Neutral at Wedbush
Low
Report
Nektar initiated with a Neutral at Wedbush
3/24
07:14 am
nktr
Nektar initiated with a Neutral at Wedbush
Low
Report
Nektar initiated with a Neutral at Wedbush
3/16
12:36 pm
nktr
Rating for NKTR
Low
Report
Rating for NKTR
3/16
12:36 pm
nktr
Rating for NKTR
Low
Report
Rating for NKTR
3/13
03:08 pm
nktr
Nektar Therapeutics (NKTR) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Low
Report
Nektar Therapeutics (NKTR) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
2/10
12:44 pm
nktr
Rating for NKTR
Medium
Report
Rating for NKTR
2/10
12:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/10
12:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/10
11:26 am
nktr
Nektar upgraded to Outperform from Market Perform at William Blair
Medium
Report
Nektar upgraded to Outperform from Market Perform at William Blair
2/10
11:26 am
nktr
Nektar upgraded to Outperform from Market Perform at William Blair
Medium
Report
Nektar upgraded to Outperform from Market Perform at William Blair
1/29
12:30 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
1/29
11:54 am
nktr
Rating for NKTR
Low
Report
Rating for NKTR